FGL vs Semax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
FGL
FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.
Full details →Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →Side-by-Side Comparison
| Aspect | FGL | Semax |
|---|---|---|
| Dose Range | 500 mcg–1 mg | 300 mcg–600 mcg |
| Frequency | 1x daily | 2x daily |
| Cycle Length | 4–8 weeks | 2–4 weeks |
| Route | intranasal | intranasal |
| Mechanism | Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. |
| Typical Dosage | Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established. | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. |
| Administration | Subcutaneous injection or intranasal administration. Research compound with limited human dosing data. | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. |
| Side Effects | Limited human data available. Animal studies show good tolerability. | Generally well-tolerated. May cause mild irritability or hair shedding in some users. |
| Best For |
What They Have in Common
FGL, Semax are both commonly used for:
Which Has Stronger Evidence?
- Cognitive Performance: Semax has stronger research support.
| Goal | FGL | Semax |
|---|---|---|
| Cognitive Performance | medium | high |
Key Studies
Semax
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology, 2025
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
Acta naturae, 2025
- The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.
Bulletin of experimental biology and medicine, 2025
Ready to Learn More?
Looking for trusted sources?